Securities Act

Cornerstone Research: Number of Securities Class Action Filings Falls to Lowest Level Since 2015

Retrieved on: 
Wednesday, July 28, 2021
Financial markets, United States securities law, Agencies of the United States government, 73rd United States Congress, U.S. Securities and Exchange Commission, Cornerstone Research, United States Securities Regulation, Securities Class Action, Class action, Securities Act, Regulation S-K, Blue sky law

This was the lowest number of filings since the first half of 2015, according to a report released today by Cornerstone Research and the Stanford Law School Securities Class Action Clearinghouse .

Key Points: 
  • This was the lowest number of filings since the first half of 2015, according to a report released today by Cornerstone Research and the Stanford Law School Securities Class Action Clearinghouse .
  • Federal and state court class actions alleging claims under the Securities Act of 1933 also declined, continuing the trend observed in 2020.
  • The report also found a sharp decline in the number of 1933 Act filings in state rather than federal court, continuing the trend observed in the Securities Class Action Filings2020 Year in Review .
  • "The better the market for investors, the worse the market for class action securities lawyers," observed Joseph A. Grundfest , director of the Stanford Law School Securities Class Action Clearinghouse, and a former commissioner of the Securities and Exchange Commission.

OTLY INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Against Oatly Group AB

Retrieved on: 
Tuesday, July 27, 2021
Financial markets, Oatly, Oats, Vegan cuisine, Securities Act, Securities Class Action, Food and drink, Law

NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Oatly Group AB ("Oatly" or the "Company") (NASDAQ: OTLY) from May 20, 2021 through July 15, 2021 (the "Class Period").

Key Points: 
  • NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Oatly Group AB ("Oatly" or the "Company") (NASDAQ: OTLY) from May 20, 2021 through July 15, 2021 (the "Class Period").
  • The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Act of 1934.
  • If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2021.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Imago BioSciences, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, July 26, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Finance, Financial markets, Money, Stock market, Initial public offering, Stifel, Underwriting, Securities Act, Myeloproliferative neoplasm, Security, Public offering, NASDAQ

Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that in connection with its previously announced public offering of its common stock, the underwriters have exercised their option to purchase an additional 1,260,000 shares of common stock from the Company.

Key Points: 
  • Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that in connection with its previously announced public offering of its common stock, the underwriters have exercised their option to purchase an additional 1,260,000 shares of common stock from the Company.
  • The gross proceeds from the exercise of the option, before deducting underwriting discounts and commissions and other offering expenses payable by Imago, were approximately $20.2 million.
  • Jefferies, Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.
  • A registration statement relating to the securities has been filed with the Securities and Exchange Commission and became effective on July 15, 2021.

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, July 23, 2021
Finance, Financial markets, Money, Stock market, Corporate finance, 73rd United States Congress, Initial public offering, Mizuho Securities, Underwriting, Securities Act, Security, Public offering

SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of$27.50per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of$27.50per share.
  • This includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares of common stock.
  • The gross proceeds toCytokineticsfrom the offering, before deducting underwriting discounts and commissions and other offering expenses payable byCytokinetics, were approximately$316.25 million.
  • Mizuho Securities and JMP Securities acted as passive book-runners, and H.C. Wainwright & Co. and Needham & Company acted as co-lead managers.

AnPac Bio Announces Appointment of New Independent Director

73rd United States Congress, U.S. Securities and Exchange Commission, Communication, Forward-looking statement, Articles, Securities Act, Securities Exchange Act, Private Securities Litigation Reform Act, Federal government of the United States, SEC Rule 10b-5

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Key Points: 
  • This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance.
  • These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET

Retrieved on: 
Thursday, July 22, 2021
SEC filings, U.S. Securities and Exchange Commission, 73rd United States Congress, Communication, Forward-looking statement, United States corporate law, Corporate governance, Agencies of the United States government, Federal government of the United States, Form 10-K, Securities Exchange Act, Securities Act

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Key Points: 
  • This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
  • You may access our Annual Report on Form 10-K for the year endedDecember 31, 2020under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov .
  • All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/lantern-pharma-to-host-second-q...

AnPac Bio Began Generating Contract Medical Device R&D Revenue

73rd United States Congress, U.S. Securities and Exchange Commission, Communication, Forward-looking statement, Securities Act, Securities Exchange Act, Private Securities Litigation Reform Act, Federal government of the United States, Economy of the United States, Human activities, SEC Rule 10b-5

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Key Points: 
  • This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance.
  • These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

DIDI SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against DiDi Global, Inc.

Retrieved on: 
Wednesday, July 21, 2021
Financial markets, Lawsuits, Securities Class Action, Stock market, Class action, DiDi, Law, Securities Act, Plaintiff, Transport

New York, New York -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of DiDi Global, Inc. ("DiDi Global" or the "Company") (NYSE: DIDI) from June 27, 2021 through July 6, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Central District of California alleges violations of the Securities Act of 1933.

Key Points: 
  • NEW YORK, July 21, 2021 (GLOBE NEWSWIRE) -- DIDI SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against DiDi Global, Inc.
    New York, New York -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of DiDi Global, Inc. ("DiDi Global" or the "Company") (NYSE: DIDI) from June 27, 2021 through July 6, 2021 (the "Class Period").
  • The lawsuit filed in the United States District Court for the Central District of California alleges violations of the Securities Act of 1933.
  • If you wish to serve as lead plaintiff, you must move the Court no later than September 7, 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

SHAREHOLDER ALERT: Robbins LLP is Investigating Array Technologies, Inc. (ARRY) on Behalf of Shareholders

Retrieved on: 
Wednesday, July 21, 2021
Legal, Professional services, 73rd United States Congress, U.S. Securities and Exchange Commission, Common law, Equity, Fiduciary, Securities Act, Securities Exchange Act, Law, Legal systems, Legal history

Shareholder rights law firm Robbins LLP is investigating Array Technologies, Inc. (NASDAQ: ARRY) to determine whether certain Array officers and directors violated the Securities Act of 1933 and Securities Exchange Act of 1934, and breached their fiduciary duties to the Company.

Key Points: 
  • Shareholder rights law firm Robbins LLP is investigating Array Technologies, Inc. (NASDAQ: ARRY) to determine whether certain Array officers and directors violated the Securities Act of 1933 and Securities Exchange Act of 1934, and breached their fiduciary duties to the Company.
  • Array purports to be one of the world's largest manufacturers of ground-mounting systems used in solar energy projects.
  • According to a complaint filed against the Company, Array's Offering Materials stated that one of the Company's strengths related to its management of costs.
  • Robbins LLP is a nationally recognized leader in shareholder rights law.

Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, July 20, 2021
U.S. Securities and Exchange Commission, Finance, Investment banks, Financial services, Evercore, Morgan Stanley, Securities Act, Registration statement, Underwriting

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 2,812,500 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Erasca, were $345.0 million. Erasca’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “ERAS.”

Key Points: 
  • The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable byErasca, were $345.0 million.
  • Erascas common stock is listed on the Nasdaq Global Select Market under the ticker symbol ERAS.
  • J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, and Guggenheim Securities acted as joint book-running managers for the offering.
  • Registration statements relating to the offering have been filed with theSecurities and Exchange Commission(SEC) and became effective onJuly 15, 2021.